The following represents disclosure information provided by authors of this abstract. The Gastrointestinal Cancers Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A phase I open-label, dose-escalation study of intravenous ascorbic acid in combination with gemcitabine and erlotinib in patients with metastatic pancreatic cancer.
Susan Joy Littman
No relevant relationships to disclose
Daniel Monti
No relevant relationships to disclose
Andrew Newberg
No relevant relationships to disclose
Anthony Bazzan
No relevant relationships to disclose
Madhavan V. Pillai
No relevant relationships to disclose
Nancy Lewis
No relevant relationships to disclose
Charles Yeo
No relevant relationships to disclose
Mark Levine
No relevant relationships to disclose
Edith P. Mitchell
No relevant relationships to disclose